GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rankning i aktier
#3670
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aktiekurs
$27.17
Marknadsvärde
$4.60B
Förändring (1 dag)
-1.33%
Förändring (1 år)
-13.30%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
Vinst för GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Vinst i Jun 2026 TTM: $159.96M
Enligt de senaste finansiella rapporterna från GlaxoSmithKline Pharmaceuticals Limited är företagets nuvarande vinst $159.96M. År 2024 hade företaget en vinst på $97.88M, en minskning jämfört med vinsten år 2023 som var $101.78M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för GlaxoSmithKline Pharmaceuticals Limited från 2004 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $159.96M | 8.59% |
| 2025 | $147.31M | 50.49% |
| 2024 | $97.88M | -3.82% |
| 2023 | $101.78M | -0.83% |
| 2022 | $102.63M | 65.48% |
| 2021 | $62.02M | 52.81% |
| 2020 | $40.59M | -58.72% |
| 2019 | $98.31M | 18.54% |
| 2018 | $82.93M | 5.21% |
| 2017 | $78.83M | -9.71% |
| 2016 | $87.30M | -9.89% |
| 2015 | $96.88M | -0.90% |
| 2013 | $97.77M | -35.64% |
| 2012 | $151.90M | -13.05% |
| 2011 | $174.69M | -10.43% |
| 2010 | $195.02M | 19.11% |
| 2009 | $163.74M | 13.31% |
| 2008 | $144.51M | -9.37% |
| 2007 | $159.46M | 24.82% |
| 2006 | $127.75M | 17.87% |
| 2005 | $108.38M | 10.05% |
| 2004 | $98.49M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $33.60B | 20,902.13% |
US
|
|
| $17.74B | 10,988.20% |
US
|
|
| $8.70B | 5,338.14% |
US
|
|
| $5.95B | 3,618.36% |
US
|
|
| $21.39B | 13,270.79% |
CH
|
